Active, not recruitingPHASE1, PHASE2NCT06405633

A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD

Studying Alpha-1-antitrypsin deficiency

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Wave Life Sciences Ltd.
Principal Investigator: Cynthia Caracta, MD
Wave Life Sciences
Intervention: WVE-006(drug)
Enrollment: 24 enrolled
Eligibility: 18-70 years · All sexes
Timeline: 2024 – 2026

Study locations (9)

St. Vincent's Hospital, Melbourne, Fitzroy, Victoria, Australia
Dalhousie University - Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
Inspiration Research Limited, Toronto, Ontario, Canada
Turku University Hospital, Turku, Finland
Universitaetsklinikum Aachen, AoeR, Aachen, Germany
Waikato Hospital, Hamilton, New Zealand
Queen Elizabeth Hospital, University Hospital Birmingham, Birmingham, United Kingdom
Cambridge University - Addenbrooke's Hospital, Cambridge, United Kingdom
Royal Free London NHS Foundation Trust, London, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06405633 on ClinicalTrials.gov

Other trials for Alpha-1-antitrypsin deficiency

Additional recruiting or active studies for the same condition.

See all trials for Alpha-1-antitrypsin deficiency →

← Back to all trials